This Was a Dose-finding Study to Evaluate Efficacy and Safety of LOU064 in Patients With CSU Inadequately Controlled by H1-antihistamines
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03926611 |
|
Recruitment Status :
Completed
First Posted : April 24, 2019
Results First Posted : February 16, 2022
Last Update Posted : April 29, 2022
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Chronic Spontaneous Urticaria | Drug: LOU064 Arm 1 Drug: LOU064 Arm 2 Drug: LOU064 Arm 3 Drug: LOU064 Arm 4 Drug: LOU064 Arm 5 Drug: LOU064 Arm 6 Drug: Placebo arm | Phase 2 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 311 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Intervention Model Description: | This was a global Phase 2b multicenter, randomized, double-blind, parallel-group, placebocontrolled study investigating the efficacy, safety and tolerability of 6 dosing groups of oral LOU064 in subjects with inadequately controlled CSU despite treatment with (second generation) H1-antihistamine. Study duration was 18 weeks (2 weeks of screening period; 12 weeks of treatment period and a 4 weeks follow-up period). Study had 7 arms: 10 mg LOU064 q.d.; 35 mg LOU064 q.d.; 100 mg LOU064 q.d.; 10 mg LOU064 b.i.d.; 25 mg LOU064 b.i.d.; 100 mg LOU064 b.i.d.; and Placebo Throughout study, subjects were treated with a 2nd generation H1-antihistamine at a locally approved licensed posology ("background medication"). Subjects could take an additional second generation H1-antihistamine that was eliminated primarily via renal excretion (e.g. cetirizine, levocetirizine or bilastine) as rescue medication. Eligible subjects could roll over to extension at Wk 12 or Wk 16 |
| Masking: | Triple (Participant, Investigator, Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | A Multicenter, Randomized, Double-blind, Placebo- Controlled Phase 2b Dose-finding Study to Investigate the Efficacy, Safety and Tolerability of LOU064 in Adult Chronic Spontaneous Urticaria (CSU) Patients Inadequately Controlled by H1-antihistamines |
| Actual Study Start Date : | June 6, 2019 |
| Actual Primary Completion Date : | January 14, 2021 |
| Actual Study Completion Date : | April 15, 2021 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: LOU064 Arm 1
10 mg LOU064 qd capsule once daily
|
Drug: LOU064 Arm 1
10 mg LOU064 orally in the morning (once daily) and matching placebo in the evening from Day 1 to 85 |
|
Experimental: LOU064 Arm 2
35 mg capsule qd LOU064 once daily
|
Drug: LOU064 Arm 2
35 mg of LOU064 orally in the morning (once daily) and matching placebo in the evening from Day 1 to 85 |
|
Experimental: LOU064 Arm 3
100 mg capsule qd LOU064 once daily
|
Drug: LOU064 Arm 3
100 mg of LOU064 orally in the morning (once daily) and matching placebo in the evening from Day 1 to 85 |
|
Experimental: LOU064 Arm 4
10 mg capsule LOU064 bid
|
Drug: LOU064 Arm 4
10mg bid of LOU064 orally, twice daily from Day 1 to 85 |
|
Experimental: LOU064 Arm 5
25 mg capsule LOU064 bid
|
Drug: LOU064 Arm 5
25 mg bid of LOU064 orally, twice daily from Day 1 to 85 |
|
Experimental: LOU064 Arm 6
100 mg capsule LOU064 bid
|
Drug: LOU064 Arm 6
100 mg bid of LOU064 orally, twice daily from Day 1 to 85 |
|
Placebo Comparator: Placebo Arm
Participants took matching placebo twice daily
|
Drug: Placebo arm
Matching placebo, orally, twice daily from Day 1 to 85 |
- Change From Baseline in Weekly Urticaria Activity Score (UAS7) at Week 4 [ Time Frame: Baseline, Week 4 ]
UAS7 score change (LS mean Change) from baseline at Week 4 estimated with a mixed-effect repeated measurement analysis of UAS7 score change from baseline (FAS)
The Urticaria Activity Score (UAS) is a composite, diary-recorded score with numeric severity intensity ratings (0=none to 3=intense/severe) for the number of wheals (hives) and the intensity of the pruritus (itch) over the past 12 hours (twice daily). The daily UAS is calculated as the average of the morning and evening scores. The UAS7 is the weekly sum of the daily UAS, which is the composite score of the intensity of pruritus and the number of wheals. The maximum UAS7 value is 42. A higher score indicates worse disease. A negative change score (week 4 score minus Baseline score) indicates improvement.
- Change From Baseline in Weekly Urticaria Activity Score (UAS7) at Week 12 [ Time Frame: Week 12 ]UAS7 score change (LS mean Change) from baseline at Week 12 estimated with a mixed-effect repeated measurement analysis of UAS7 score change from baseline (FAS)
- Percentage of Participants With Either Complete Absence of Hives and Itch (UAS7=0) or Well-controlled Disease (UAS7<=6) [ Time Frame: Week 12 ]UAS7=0 and UAS7<=6 response rate over time by treatment group (non-responder imputation) The UAS7 is the weekly sum of the daily UAS, which is the composite score of the intensity of pruritus and the number of wheals. The maximum UAS7 value is 42. A higher score indicates more severe disease. A negative change score (week 4 score minus Baseline score) indicates improvement.
- Cumulative Number of Weeks With an AAS7=0 Response [ Time Frame: Baseline to Week 12 ]The Weekly angioedema activity score (AAS) is a validated tool to assess occurrence of episodes of angioedema. If the subject reports the occurrence of angioedema ("opening question") with "no", AAS score for this day is 0. If "yes" is the answer to the opening question, the subject will continue to answer questions about the duration, severity and impact on daily functioning and appearance of the angioedema. The AAS7 is a weekly AAS score (AAS7). Minimum and maximum possible AAS7 scores are 0-105. Higher score means more severe disease.
- Percentage of Participants With DLQI Score of 0 or 1 [ Time Frame: Week 4 and Week 12 ]
Percentage of subjects with DLQI 0/1 response by treatment group and visit (non-responder imputation)
The Dermatology Life Quality Index (DLQI) is a 10-item dermatology-specific quality of life (QoL) measure. Subjects rate their dermatology symptoms as well as the impact of their skin condition on various aspects of their lives thinking about the previous 7 days. An overall score is calculated and ranges from 0 to 30 (higher score meaning worse disease-related QoL). A DLQI score of 0 or 1 means that there is no impact of a skin disease on the patient's life.
- Mean Change From Baseline in DLQI Score [ Time Frame: Baseline, Week 4 and Week 12 ]
Summary of DLQI score and change from baseline
The Dermatology Life Quality Index (DLQI) is a 10-item dermatology-specific quality of life (QoL) measure. Subjects rate their dermatology symptoms as well as the impact of their skin condition on various aspects of their lives thinking about the previous 7 days. An overall score is calculated and ranges from 0 to 30 (higher score meaning worse disease-related QoL).
- Area Under the Blood Concentration-time Curve (AUC) of LOU064 [ Time Frame: Week 4 and Week 12 ]Assessment of the area under the blood concentration-time curve (AUC) up to four hours following oral administration at Week 4 and Week 12 .
- Observed Maximum Blood Concentration (Cmax) of LOU064 [ Time Frame: Week 4 and Week 12 ]Assessment of the observed maximum blood concentration (Cmax) of LOU064 following drug administration at Week 4 and Week 12 .
- Time to Reach the Maximum Concentration (Tmax) of LOU064 [ Time Frame: Week 4 and Week 12 ]Assessment of the time to reach the maximum concentration (Tmax) of LOU064 following drug administration at Weeks 4 and 12
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 99 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Male and female subjects aged ≥18 years of age
- CSU diagnosis for ≥ 6 months prior to screening
- Presence of itch and hives for ≥6 consecutive weeks prior to screening in spite of use of non-sedating H1-antihistamines according to local Treatment guidelines during this time period
- UAS7 score (range 0-42) ≥16 and HSS7 score (range 0-21) ≥ 8 during 7 days prior to randomization (Day 1)
- Willing and able to complete an Urticaria Participant Daily eDiary (UPDD) for the duration of the study
Exclusion Criteria:
- Hypersensitivity to any of the study treatments
- Clearly defined predominant or sole trigger of their chronic urticaria (chronic inducible urticaria)
- Other diseases with symptoms of urticaria or angioedema
- Other skin disease associated with chronic itching that might influence in the investigators opinion the study evaluations and results,
- Known or suspected history of an ongoing, chronic or recurrent infectious disease including but not limited to opportunistic infections (eg tuberculosis, atypical mycobacterioses, listeriosis or aspergillosis), HIV, Hepatitis B/C.
- Pregnant or nursing (lactating) women
- Women of child-bearing potential not using highly effective methods of contraception
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03926611
Show 82 study locations
| Study Director: | Novartis Pharmaceuticals | Novartis Pharmaceuticals |
Documents provided by Novartis ( Novartis Pharmaceuticals ):
| Responsible Party: | Novartis Pharmaceuticals |
| ClinicalTrials.gov Identifier: | NCT03926611 |
| Other Study ID Numbers: |
CLOU064A2201 2018-000993-31 ( EudraCT Number ) |
| First Posted: | April 24, 2019 Key Record Dates |
| Results First Posted: | February 16, 2022 |
| Last Update Posted: | April 29, 2022 |
| Last Verified: | April 2022 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Undecided |
| Plan Description: | Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
|
BTK inhibitor Urticaria Activity Score Angioedema Activity Score CSU |
|
Urticaria Chronic Urticaria Skin Diseases, Vascular Skin Diseases Hypersensitivity, Immediate |
Hypersensitivity Immune System Diseases Chronic Disease Disease Attributes Pathologic Processes |